Aeterna Acquires Rights to Develop Therapy for Primary Hypoparathyroidism
Aeterna Zentaris has entered into a licensing agreement with the University of Sheffield  to develop a potential therapy for adults with primary hypoparathyroidism, according to a recent press release. The treatment candidate is based on parathyroid hormone (PTH) fusion polypeptides — chains of amino acids, the building blocks…